KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 109.95%.

  • TherapeuticsMD's EBITDA Margin rose 973600.0% to 109.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 61.8%, marking a year-over-year increase of 3108800.0%. This contributed to the annual value of 270.3% for FY2024, which is 5191000.0% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's EBITDA Margin is 109.95%, which was up 973600.0% from 73.0% recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EBITDA Margin registered a high of 32264.66% during Q2 2022, and its lowest value of 8182.2% during Q3 2022.
  • Over the past 5 years, TherapeuticsMD's median EBITDA Margin value was 207.31% (recorded in 2024), while the average stood at 332.13%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 324500900bps in 2022, then crashed by -328170600bps in 2023.
  • Over the past 5 years, TherapeuticsMD's EBITDA Margin (Quarter) stood at 230.0% in 2021, then soared by 149bps to 113.32% in 2022, then plummeted by -255bps to 175.9% in 2023, then skyrocketed by 160bps to 104.95% in 2024, then plummeted by -205bps to 109.95% in 2025.
  • Its EBITDA Margin stands at 109.95% for Q3 2025, versus 73.0% for Q2 2025 and 221.63% for Q1 2025.